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Abstract  1 
Increased endothelial cell apoptosis is associated with the development of atherosclerotic 2 
plaques that develop predominantly at sites exposed to disturbed flow. Strategies to promote 3 
endothelial cell survival may therefore represent a novel therapeutic approach in 4 
cardiovascular disease. Nitric oxide (NO) and β-catenin have both been shown to promote cell 5 
survival and they interact in endothelial cells as we previously demonstrated. Here we 6 
investigated the physiological role of β-catenin as a mediator of NO-induced cell survival in 7 
endothelial cells. We found that β-catenin depleted human umbilical vein endothelial cells 8 
(HUVEC) stimulated with pharmacological activators of endothelial NO synthase (eNOS) 9 
showed a reduction in eNOS phosphorylation (Ser1177) as well as reduced intracellular cyclic 10 
guanosine monophosphate (cGMP) levels compared to control cells in static cultures. In 11 
addition, β-catenin depletion abrogated the protective effects of the NO donor, SNAP, during 12 
TNFα- and H2O2-induced apoptosis. Using an orbital shaker to generate shear stress, we 13 
confirmed eNOS and β-catenin interaction in HUVEC exposed to undisturbed flow (UF) and 14 
disturbed flow (DF) and showed that β-catenin depletion reduced eNOS phosphorylation. β-15 
catenin depletion promoted apoptosis exclusively in HUVEC exposed to DF as did inhibition 16 
of soluble guanylate cyclase (sGC) or β-catenin transcriptional activity. The expression of the 17 
pro-survival genes, Bcl-2 and survivin was also reduced following inhibition of β-catenin 18 
transcriptional activity, as was the expression of eNOS. In conclusion, our data demonstrate 19 
that β-catenin is a positive regulator of eNOS activity and cell survival in human endothelial 20 
cells. sGC activity and β-catenin-dependent transcription of Bcl-2, survivin, BIRC3 and eNOS 21 
are essential to maintain cell survival in endothelial cells under DF.  22 
  23 
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Introduction 1 
Apoptosis is implicated in a number of cardiovascular diseases, in particular the development 2 
and progression of atherosclerosis, plaque rupture, ischaemia reperfusion injury and heart 3 
failure1. Increased endothelial cell (EC) apoptosis is associated with the development of 4 
atherosclerotic plaques2, vascular injury3 and raised vessel permeability4. Strategies to 5 
promote cell survival may therefore be important in reducing cardiovascular disease.  6 
 7 
Atherosclerosis is characterised by dysfunction of the vascular endothelium which is 8 
associated with reduced bioavailability and bioactivity of nitric oxide (NO)5. Endothelial NO 9 
synthase (eNOS), the main vascular source of NO, confers protection from cardiovascular 10 
disease6, through a number of mechanisms including inhibition of EC apoptosis7,8,9,10,11. 11 
Similarly, laminar shear stress prevents TNFα and H2O2-induced apoptosis and this effect is 12 
dependent on eNOS activity9. NO has previously been shown to inhibit apoptosis at several 13 
levels; via S-nitrosylation of caspases8,12, increased expression and stability of Bcl-2 by 14 
destabilization of MKP-3 mRNA13 and inhibition of JNK signalling pathways7,14.  Recently we 15 
identified β-catenin as a novel eNOS binding partner in human umbilical vein EC (HUVEC) 16 
and showed that pharmacological activation of eNOS, acting through sGC and cGMP, 17 
promotes nuclear translocation of β-catenin and transcription of some β-catenin target genes 18 
providing evidence of a novel signalling axis in EC15.  19 
 20 
β-catenin is a component of the adherens junction, linking VE-cadherin to the actin 21 
cytoskeleton, where it plays an important role in the dynamic regulation of endothelial 22 
permeability16. Non-junctional (cytosolic) β-catenin is rapidly degraded under resting 23 
conditions by interacting with an inhibitory complex comprised of APC, axin and GSK-3β that 24 
phosphorylates β-catenin and targets it for ubiquitin-mediated degradation16. Cytosolic β-25 
catenin can be stabilised by canonical and non-canonical Wnt signalling pathways and, as 26 
recently established, by NO-cGMP signalling15, whereby dephosphorylated (active) β-catenin 27 
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accumulates and translocates to the nucleus where it regulates gene expression through its 1 
interaction with TCF-LEF transcription factors16. A subset of β-catenin target genes are 2 
associated with anti-apoptotic (cell survival) functions raising the possibility that NO may 3 
promote cell survival through transcriptional activation of β-catenin.  4 
 5 
Here we sought to assess the role of β-catenin in eNOS signalling and the physiological role 6 
of the NO-cGMP-β-catenin axis on apoptosis in EC under disturbed (atheroprone) or 7 
undisturbed (atheroprotective) flow.  8 
 9 
 10 
Materials and methods 11 
 12 
Cell culture, transfection and application of shear stress 13 
HUVEC were purchased from Promocell as pools from several donors and cultured in 14 
Promocell Endothelial Cell Growth Medium (containing 2% FCS). Cells were cultured at 37°C 15 
and 5% CO2 and confluent HUVEC at up to passage 6 were used for experiments. Human 16 
aortic endothelial cells (HAEC) from single donors were purchased from Promocell and 17 
cultured on fibronectin in Endothelial Growth Medium MV (Promocell). HAEC were used up to 18 
passage 6. Mouse pulmonary endothelial cells (MPEC) were cultured as previously 19 
described15. Culture media was supplemented with 100 U/ml penicillin and 100 µg/ml 20 
streptomycin. Antibiotic free media was used for the cell assays and added before application 21 
of flow (see below) and/or before a treatment was added.  At least 3 different biologically 22 
independent cell batches were studied for each experiment. 23 
 24 
RNA interference was performed using siRNA sequences specific for human target genes. 25 
Non-targeting scrambled sequences were used as a control. HUVEC were transfected with 26 
siRNAs (100nM) using Lipofectamine RNAiMAX (Invitrogen) in serum-free media (Optimem, 27 
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Invitrogen) without antibiotics. Medium was changed to growth medium 16 h after transfection. 1 
Scrambled control and β-catenin siRNA pool was purchased from Ambion and Santa Cruz 2 
respectively.  3 
 4 
For assays in which application of flow was required, an orbital shaker was used. EC were 5 
seeded at passage 3-7 onto fibronectin-coated 6-well plates. Where experiments required 6 
immunostaining, EC were seeded onto fibronectin-coated glass-bottom plates (In vitro 7 
scientific). Once monolayers were confluent (after 24-48hrs), media was changed and the 6-8 
well plates were placed onto an orbital rotating platform (Grant Instruments) housed inside the 9 
incubator and cultured for a further 72 h. The radius of orbit of the orbital shaker was 10 mm 10 
and the rotation rate was set to 150 rpm which caused swirling of the culture medium over the 11 
cell surface that creates distinct flow patterns at the centre and edge of the well; cells at the 12 
edge are exposed to undisturbed uniaxial flow (UF) whereas cells at the centre are exposed 13 
to disturbed, multidirectional flow (DF)17. 14 
 15 
For transfection of HUVEC for flow experiments, immediately prior to seeding into 6-well 16 
plates, HUVEC were transfected with 100nM MISSION® pre-designed and validated siRNA 17 
targeting β-catenin (Sigma) or 100 nM scrambled control (Ambion) by electroporation. 18 
Electroporation was carried out using a Neon™ Transfection System according to 19 
manufacturer’s instructions. Cells were seeded at a density of 1x105 cells per well and cultured 20 
under static conditions for ~6h to allow cells to adhere and become confluent before exposure 21 
to flow using the orbital shaker method. For analysis of protein expression, 3 wells were pooled 22 
for each flow condition. Knockdown of target proteins was confirmed by western blot for each 23 
experiment. 24 
 25 
EC were exposed to disturbed or undisturbed flow for 72h using an orbital shaker (150rpm; 26 
Grant Instruments) housed inside the incubator17,18. At least 3 different biologically 27 
independent cell batches were studied for each experiment. 28 
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 1 
Cell lysis, fractionation and western blotting 2 
Cells were lysed in ice-cold RIPA buffer (1% Triton-X 100, 1% sodium deoxycholate, 2.5 3 
mmol/l ethylenediaminetetraacetic acid (EDTA), 100 mmol/l NaCl, 20mmol/l Tris-base; pH 7.4) 4 
supplemented with protease and phosphatase inhibitor cocktails (Roche). Lysates were 5 
incubated on ice for 45 min, then centrifuged for 10 min at 16,000g to separate soluble from 6 
insoluble fractions.  7 
 8 
Cell surface and cytosolic extracts were separated from nuclear. Cells were scraped, washed 9 
with phosphate-buffered saline (pH 7.4), resuspended in hypotonic buffer (10 mM Hepes (pH 10 
7.9), 1.5 mM MgCl2, 10 mM KCl, 0.2 mM phenylmethylsulfonyl fluoride, and 0.5 mM 11 
dithiothreitol), and allowed to swell on ice for 10 min. After that 1% NP40 was added and the 12 
cells were homogenized with a syringe and needle and vortexed for 2 min. The nuclei were 13 
separated by spinning at 3300g for 5 min at 4 °C. The supernatant was used as soluble 14 
cytoplasmic/membrane extract. The nuclear pellet was extracted in nuclear extraction buffer 15 
(20 mM Hepes (pH 7.9), 100mM NaCl, 1.5 mM MgCl2, 1% Triton, 1 mM EDTA, 1 mM EGTA, 16 
10% glycerol, 0.5 % deoxycholate, 0.1% SDS with protease and phosphatase inhibitor 17 
cocktails (Roche)) for 30 min on ice and centrifuged at 12,000g for 30 min. The supernatant 18 
was used as a nuclear extract.  19 
 20 
Soluble nuclear and cytoplasmic/membrane protein lysates were analysed by SDS-PAGE and 21 
immunoblotting. Bound antibodies were visualised with horseradish peroxidase-conjugated 22 
anti-IgG antibodies and enhanced chemiluminescence susbtrates (Thermo Scientific). 23 
Antibodies for western blotting were obtained from the following sources: anti cleaved caspase 24 
3, total caspase 3, β-catenin, eNOS, eNOS phosphoS1177, Calnexin, cIAP1, TBP (Cell 25 
Signalling), β-catenin, active β-catenin, VE-cadherin, eNOS phosphoS635, eNOS 26 
phosphoS114 (BD Biosciences), NOS3, PDHX and GAPDH (Santa Cruz). 27 
 28 
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cGMP ELISA   1 
Lysates were extracted by addition of 0.1 mol/L HCl supplemented with 1 mmol/L 3-isobutyl-2 
1-methylxanthine. cGMP concentration was assessed following acetylation using Cyclic GMP 3 
EIA Kit (Cayman Chemicals) according to the manufacturer's instructions. Resulting cGMP 4 
concentrations were normalized to protein content per sample. 5 
 6 
Immunostaining and confocal microscopy    7 
HUVEC on fibronectin-coated glass plates (In vitro scientific IBL) were fixed with 4% 8 
paraformaldehyde solution for 20 min, permeabilized with 0.1% Triton X-100 in PBS for 5 min 9 
and blocked with 5% BSA in PBS for a further 30 min. Cells were incubated overnight at 4°C 10 
with anti-cleaved caspase 3 antibody (cell signalling), active β-catenin (BD biosciences) or 11 
VE-Cadherin (BD Biosciences) or active β-catenin (Millipore) and/or 4',6-diamidino-2-12 
phenylindole (DAPI) to stain nuclei.  Images were generated with a Nikon Spinning disk 13 
confocal microscope using a 20x objective and Nikon software. The percentage of cleaved 14 
caspase 3 positive cells was calculated in at least 16 randomly selected fields of view for each 15 
condition, covering approximately 2000-4000 cells to estimate the level of apoptosis. 16 
 17 
En face staining of mouse aortas 18 
All procedures were conducted in accordance with the Directive 2010/63/EU of the European 19 
Parliament on the protection of animals used for scientific purposes, as enforced by national 20 
legislation, the UK Animal (Scientific Procedures) Act 1986 (as amended), under authorisation 21 
of the UK Home Office (Project License No. 70-8934). Male, 8-week-old C57BL/6J mice were 22 
purchased from Charles River Laboratories (Harlow, UK), maintained on a 12-hour day/night 23 
cycle, and fed a standard breeding/maintenance chow ad libitum (RM3, Special Diets 24 
Services, UK) for two weeks prior to tissue harvest. Mice were terminally anaesthetised with 25 
an overdose of pentobarbitone (120 mg/kg i.p.) then perfused transcardially with an ice-cold 26 
0.9% saline, 100 U/ml heparin solution, followed by ice-cold 4% paraformaldehyde (Parafix, 27 
Pioneer Research Chemicals Ltd, UK). Aortas were removed intact from the heart to the renal 28 
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bifurcation, further post-fixed in 4% paraformaldehyde at 4°C overnight, then micro-dissected 1 
under a stereomicroscope in 0.1 M phosphate buffered saline to produce en face preparations. 2 
Co-localization of eNOS (C-20; Santa Cruz) and β-catenin (BD biosciences) was visualised in 3 
EC from wild type C57BL/6 mice by en face staining of susceptible (inner curvature) or 4 
protected (outer curvature) regions of the aorta followed by laser scanning confocal 5 
microscopy. Nuclei were stained with DAPI.  6 
 7 
Proximity ligation assay 8 
Proximity ligation assays were carried out using a Duolink In-Situ Detection Kit as previously 9 
described15. HUVEC were cultured in 6-well plates until confluent and subjected to flow for 72 10 
h using an orbital shaker. Following flow exposure, cells were fixed with 4% paraformaldehyde 11 
then permeabilized with 0.5% Triton®X-100. In situ proximity ligation assay (PLA) was carried 12 
out using rabbit anti-eNOS and mouse anti- β-catenin primary antibodies in combination with 13 
Duolink In Situ Red Detection Kit (Sigma). PLA was carried out according to the 14 
manufacturer’s instructions. Afterwards cells were washed to eliminate excess of reagents 15 
and cells were counterstained with 4',6-diamidino-2-phenylindole (DAPI) and VE-Cadherin 16 
(BD Biosciences) to visualize cell junctions and nuclei respectively. Images were generated 17 
with a Nikon Spinning disk confocal microscope using a 20x objective and Nikon software NIS 18 
elements. PLA analysis was carried out on confocal images. Approximately 2000 cells from 4 19 
independent experiments were quantified. The PLA signal intensity per cell was analysed 20 
using Image J and the particle analysis function on PLA images and cells numbers calculated 21 
using the same function on DAPI images. A mask for the cell edge was generated with the 22 
VE-cadherin image and imposed over the PLA image to measure signal inside and outside of 23 
the mask. 24 
 25 
 26 
TUNEL assay 27 
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To detect DNA fragmentation in apoptotic cells, terminal transferase dUTP Nick End Labelling 1 
(TUNEL) was performed as previously described19. A Click-iT TUNEL Alexa Fluor 594 Imaging 2 
Assay was used following the manufacturer instructions (Life technologies). Briefly cells were 3 
fixed using 4% paraformaldehyde in PBS for 15 min and followed by a permeabilization step 4 
with 0.25% Triton®X-100 for 20 min. Cells were then treated with terminal deoxynucleotidyl 5 
transferase (TdT) for 60 minutes at 37°C to allow the incorporation of modified dUTPs at the 6 
3’-OH ends of fragmented DNA, followed by a Click-iT® reaction for 30 min at 37°C to label 7 
ends with a fluorescent dye through click chemistry. Afterwards cells were washed gently to 8 
eliminate excess of reagents and cells were counterstained with 4',6-diamidino-2-phenylindole 9 
(DAPI) and VE-Cadherin (BD Biosciences) to visualize the cell edges and nuclei respectively. 10 
Images were generated with a Nikon Spinning disk confocal microscope using a 20x objective 11 
and Nikon software NIS elements. The percentage of TUNEL positive cells was calculated in 12 
16 selected fields of view for each condition, covering approximately 2000-4000 cells to 13 
estimate the level of apoptosis.  14 
 15 
RNA isolation and quantitative RT-PCR  16 
RNA was isolated from cells using RNeasy Mini kits (Qiagen).  Contaminating DNA was 17 
removed by on-column DNase digestion (Qiagen).  cDNA was prepared using a High-Capacity 18 
Reverse Transcription Kit (Thermo Scientific). Quantitative real-time PCR (qPCR) was carried 19 
out with cDNA using SYBR green mastermix (Primer Design). GADPH was used as a 20 
reference gene. The qPCR oligonucleotide primers used for eNOS were: F: 21 
CATCTTCAGCCCCAAACGGA R: AGCGGATTGTAGCCTGGAAC; for Survivin: F: 22 
TGAGAACGAGCCAGACTTGG R: TGTTCCTCTATGGGGTCGTCA; for KLF-2: F: 23 
TGGGCATTTTTGGGCTACCT R: CCCAGTTCCAAGCAACCAGA; for E-SEL: F: 24 
GCTCTGCAGCTCGGACAT R: GAAAGTCCAGCTACCAAGGGAAT; for Bcl-2: F: 25 
ATGTGTGTGGAGAGCGTCAA R: GGGCCGTACAGTTCCACAAA; for GAPDH: F: 26 
CTATAAATTGAGCCCGCAGCC R: ACCAAATCCGTTGACTCCGA; for XIAP: F: 27 
AGTGTCTGGTAAGAACTACTG R: CCCATTCGTATAGCTTCTTG; for WISP-1: F:  28 
10 
 
TCATTAAGGCAGGGAAGAAG R: GTCTTAGACTTGTAGGGGATG; for BIRC3: F: 1 
ACAAGCAAGAGAACTGATTG R: GATCTGAAACATCTTCTGTGG and for Caspase 3 F: 2 
AAAGCACTGGAATGACATC R: CGCATCAATTCCACAATTTC. The amplification process 3 
included one cycle of 10 min at 95°C, 40 cycles for 15 s at 95°C, followed by 40 cycles for 1 4 
min at 60°C. Thermal cycling and fluorescence detection were performed using an ABI 7500 5 
Fast Prism (PE Applied Biosystems, Foster City, CA, USA). 6 
 7 
Apoptosis gene expression array 8 
HUVEC were cultured in 6-well plates until confluent and subjected to flow for 72 h using an 9 
orbital shaker. Following flow exposure, cells were washed twice with cold PBS and total DNA 10 
free mRNA was isolated using RNeasy Mini kits (Qiagen) and on-column DNase digestion as 11 
described above. mRNA integrity and concentration were determined spectrophotometrically. 12 
An RT2 Profilertm polymerase chain reaction (PCR) apoptosis array (PAHS-012ZA-Qiagen) 13 
was performed according to the manufacturer’s instructions. Briefly, a total of 0.5 μg of RNA 14 
per sample was used with the RT2 First Strand kit (Qiagen) to obtain cDNA after incubation 15 
for 5 min with the gDNA elimination buffer. The PCR amplification process included one cycle 16 
of 10 min at 95°C, 40 cycles for 15 s at 95°C, followed by 40 cycles for 1 min at 60°C. Thermal 17 
cycling and fluorescence detection were performed using an ABI 7500 Fast Prism (PE Applied 18 
Biosystems, Foster City, CA, USA). The signals of the target cDNAs were normalized by 19 
comparison with the housekeeping genes HPRT1 supplied within the 96-well microtiter plate. 20 
The normalized amount of each target mRNA present in each condition was calculated using 21 
a comparative Ct method and using a web-based PCR array data analysis tool 22 
(https://www.qiagen.com/gb/shop/genes-and-pathways/data-analysis-center-overview-23 
page/) with 1.5-fold difference set as baseline. 24 
 25 
Statistical analysis 26 
All data are presented as mean ± SEM. Statistical analysis was performed using GraphPad 27 
Prism software (v7.1). Statistical significance was assessed using paired two-tailed t-test (for 28 
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comparing two conditions) or by one-way analysis of variance (ANOVA) with repeated 1 
measures for multiple conditions. Each n is generated with a separate batch of ECs. For 2 
HUVEC these are pools of cells from different donors and for HAEC, in each batch EC had 3 
been isolated from a single donor. When using one-way ANOVA, tests for equal variance were 4 
run and if significantly different standard deviations were found (thus different variances) in 5 
the ANOVA with repeated measures a Gaussian distribution and no sphericity (not equal 6 
variability of the differences) was assumed and the Greenhouse-Geisser correction applied. 7 
 8 
 9 
 10 
Results 11 
β-catenin regulates eNOS activity in static HUVEC 12 
To investigate whether β-catenin regulates eNOS activation in HUVEC, we assessed eNOS 13 
phosphorylation in cells following transfection with a pool of β-catenin siRNA oligonucleotides 14 
or an siRNA scrambled control pool. β-catenin depletion did not alter basal levels of eNOS 15 
phosphorylation (Figure 1A-B and S1A-B), however it did reduce agonist-induced eNOS 16 
phosphorylation on Ser1177 (Figure 1A and S1A). Interestingly, β-catenin depletion had no 17 
effect on agonist-induced eNOS phosphorylation on Ser633 (Figure 1B and S1B). Intracellular 18 
cGMP levels are a well-established indicator of bioactive NO levels; we observed that in 19 
HUVEC, the histamine-induced increase in cGMP production was reduced following depletion 20 
of β-catenin with siRNA (Figure 1C). The absence of β-catenin protein in HUVEC transfected 21 
with β-catenin siRNA was confirmed by western blotting (Figure S1C), furthermore, eNOS 22 
expression was not altered in β-catenin knockdown static cells (Figure S1D).  23 
 24 
To confirm that β-catenin can promote eNOS phosphorylation on Ser1177 and thus increase 25 
NO and cGMP production, we treated HUVEC with LiCl that inhibits GSK3β-dependent 26 
phosphorylation of β-catenin and promotes its accumulation. We found that elevating β-27 
12 
 
catenin levels with LiCl increased eNOS phosphorylation on Ser1177 but had no effect on 1 
Ser633 in static HUVEC (Figure 1D-F). Together these data demonstrate that β-catenin 2 
enhances agonist-dependent eNOS activation and subsequent cGMP production in HUVEC 3 
under static conditions. 4 
 5 
β-catenin mediates the anti-apoptotic effects of NO-cGMP in static HUVEC 6 
Since reduction of β-catenin may impair eNOS function and since NO is an important factor 7 
for EC survival7, we assessed the potential protective effects of β-catenin, in relation to NO 8 
signalling, in static cultures following induction of apoptosis. In wild-type MPEC application of 9 
an NO donor (S-nitroso-N-acetylpenicillamine; SNAP) attenuated TNFα-induced apoptosis, 10 
indicated by a lower number of cleaved caspase-3 positive cells in the presence of SNAP, 11 
however in β-catenin-/- MPEC, the protective effects of SNAP on TNFα-induced apoptosis were 12 
abrogated (Figure 2A). We also examined TNFα-induced apoptosis in HUVEC and observed 13 
that siRNA depletion of β-catenin reduced the anti-apoptotic action of SNAP in this context 14 
(Figures 2B, 2E and S1E), demonstrating that β-catenin also mediates the pro-survival effects 15 
of NO in human EC under static conditions. Since β-catenin appears to regulate the level of 16 
activated eNOS and subsequent cGMP production in HUVEC, we examined activation of 17 
caspase-3 by H2O2 in HUVEC in the presence of sildenafil, a pharmacological sGC activator. 18 
Whilst cleaved caspase-3 levels induced by H2O2 are reduced by sildenafil treatment in 19 
scrambled control-treated cells, this was not the case in β-catenin depleted HUVEC (Figure 20 
2C). Furthermore, ODQ, a pharmacological sGC inhibitor, abrogated the protective effects of 21 
SNAP in the presence of H2O2 (Figure 2D), indicating that NO exerts its anti-apoptotic effects 22 
through sGC activation and cGMP production. Together these data suggest that β-catenin 23 
mediates the pro-survival effects of NO and cGMP upon pharmacological (non-physiological) 24 
induction of apoptosis in static EC. eNOS expression and activation is known to increase in 25 
EC exposed to undisturbed flow18 and enhanced endothelial NO synthesis promotes survival 26 
of EC under physiological levels of shear stress against TNFα and H2O2 8,9. For these reasons 27 
13 
 
we next sought to determine whether β-catenin mediates the pro-survival effects of NO under 1 
physiological flow conditions.  2 
 3 
β-catenin associates with eNOS in HUVEC exposed to physiological flow  4 
To confirm our previous observation made in static EC15, and to test whether eNOS and β-5 
catenin interact under physiological flow conditions, we carried out a proximity ligation assay 6 
(PLA) in HUVEC subjected to flow for 72h. We used an orbital shaking platform to generate 7 
reproducible spatially separated atheroprotective (undisturbed; uniaxial, high wall shear 8 
stress) and atheroprone (disturbed; multiaxial, low wall shear stress) flow patterns17,18. As 9 
previously described, HUVEC growing under atheroprotective, undisturbed flow (UF) were 10 
elongated and aligned meanwhile the cells in the atheroprone, disturbed flow (DF) central 11 
region showed a non-aligned mosaic-like morphology (Figure 3A and S2A). Furthermore, EC 12 
in the UF region expressed high levels of KLF2 and KLF4 and lower levels of MCP-1 and E-13 
selectin compared to EC exposed to DF20,21 (Figure S2B). Co-localization was observed in EC 14 
fixed and stained with anti-eNOS and anti-β-catenin antibodies (Figure S2A) and amplification 15 
products were detected by PLA indicating proximity (< 40nm) of both proteins in HUVEC 16 
exposed to both UF and DF (Figure 3A) but not in controls stained separately with either anti-17 
eNOS or anti-β-catenin antibody. The average PLA signal per cell was lower in EC exposed 18 
to UF (Figure 3A) consistent with increased eNOS activity15. β-catenin and eNOS also co-19 
localise in vivo in ECs of the inner and outer curvature of the aortic arch, regions of disturbed 20 
and undisturbed flow respectively, however co-localization was more prominent in the inner 21 
aortic arch (Figure 3B). In contrast with observations made in HUVEC subjected to acute low 22 
magnitude shear stress22, no difference in the subcellular localization of β-catenin was 23 
observed in HUVEC exposed to chronic flow using an orbital shaker (Figure S2C). 24 
 25 
β-catenin regulates eNOS phosphorylation in HUVEC exposed to physiological flow  26 
Since activation of eNOS causes dissociation from β-catenin in static cells15, the higher level 27 
of interaction observed in EC exposed to DF suggests lower activation of eNOS in these cells. 28 
14 
 
We thus measured eNOS phosphorylation on Ser1177, Ser633 and Ser114 and observed 1 
lower eNOS phosphorylation in EC exposed to DF compared to those exposed to UF (Figure 2 
4A). To investigate whether β-catenin regulates eNOS activation in HUVEC exposed to flow, 3 
we assessed eNOS phosphorylation in HUVEC following transfection with β-catenin siRNA or 4 
a siRNA scrambled control and exposed to flow for 72h (Figure 4B). We observed that eNOS 5 
phosphorylation on Ser1177 decreased in EC exposed to UF when β-catenin was depleted 6 
but not in EC exposed to DF, consistent with our findings in static EC. eNOS expression was 7 
not altered by β-catenin knockdown, compared with scrambled control transfection, although 8 
eNOS expression was different in EC exposed to DF compared to UF (Figure S2D); but 9 
interestingly, phosphorylation on Ser114 was reduced in both UF and DF exposed HUVEC 10 
when β-catenin was depleted (Figure 4B). In contrast, treatment of HUVEC with LiCl increased 11 
Ser1177 phosphorylation in both regions (Figure 4C), confirming that β-catenin interacts with 12 
and can activate eNOS under physiological and atheroprone flow conditions. 13 
 14 
Deletion of β-catenin increases apoptosis only in HUVEC exposed to disturbed flow 15 
Atheroprotective, laminar flow activates eNOS and is the predominant source of NO in ECs. 16 
It has also been associated with EC survival8,10. In contrast, atherogenic shear stress profiles 17 
are associated with reduced expression of pro-survival genes and increased apoptosis, both 18 
in vitro and in vivo23,24. We measured apoptosis by cleaved caspase-3 staining of HUVEC 19 
subjected to flow using an orbital shaker and observed that the percentage of apoptosis was 20 
higher under DF compared to UF as expected (Figure S3A). Having established the 21 
involvement of β-catenin in NO-mediated anti-apoptotic activity in static cultures, we sought 22 
to determine the pro-survival actions of NO and β-catenin under physiological flow conditions. 23 
Inhibition of sGC activity with ODQ in HUVEC subjected to shear stress for 72h, increased 24 
apoptosis of HUVEC exposed to DF as assessed by cleaved caspase-3 immunostaining 25 
(Figure 5A). Furthermore, depletion of β-catenin in HUVEC promoted apoptosis exclusively in 26 
HUVEC exposed to DF (Figure 5B and S3B). In agreement with the higher level of apoptotic 27 
cells observed in DF exposed HUVEC, we also detected higher levels of cleaved caspase-3 28 
15 
 
in lysates from HUVEC subjected to DF for 72h (Figure S3C). Unexpectedly we found that the 1 
expression level of procaspase-3 (35 kDa) was lower in lysates from EC exposed to UF 2 
compared to DF (Figure 5C), though caspase-3 mRNA expression showed only a 20% 3 
increase in cells exposed to DF compared to UF (Figure S3D), suggesting that a post-4 
translational mechanism may be regulating the protein expression and/or stability of caspase-5 
3 in HUVEC exposed to UF.  6 
 7 
Inhibition of β-catenin transcriptional activity increases apoptosis in HUVEC exposed 8 
to disturbed flow 9 
Since β-catenin can regulate the expression of pro-survival genes and has also been shown 10 
to act downstream of eNOS/NO/cGMP, we investigated whether inhibiting its transcriptional 11 
activity also influenced cell survival under flow conditions. Inhibition of β-catenin-dependent 12 
transcriptional activation with the specific inhibitors of β-catenin/TCF-LEF interaction, iCRT5 13 
or FH53525,26, also exclusively increased apoptosis in HUVEC under DF in the same 14 
conditions (Figure 5D and S3E) and in HAEC exposed to DF (Figure S3F). The low level of 15 
apoptosis observed under UF was not altered by any method used to manipulate eNOS or β-16 
catenin signalling (Figure 5A-E and S3E-G). Whilst treatment with histamine, which 17 
upregulates eNOS, reduced apoptosis in HUVEC exposed to DF (Figure 5E), inhibition of 18 
eNOS with 100mM L-NAME did not affect apoptosis in HUVEC exposed to either DF or UF 19 
(Figure S3G). These data indicate that signalling through sGC and β-catenin is essential to 20 
maintain cell survival in EC exposed to DF and that other additional mechanisms contribute to 21 
cell survival in UF-exposed HUVEC. 22 
 23 
Inhibition of β-catenin-dependent transcription downregulates the expression of anti- 24 
apoptotic genes in HUVEC under flow 25 
As the inhibition of cGMP signalling and β-catenin-dependent transcription increases 26 
apoptosis in HUVEC exposed to DF, we studied the expression of several anti-apoptotic genes 27 
that are potential targets of β-catenin: XIAP, WISP-1, Bcl-2 and survivin (BIRC5). Bcl-2 and 28 
16 
 
survivin exhibited differential expression between DF and UF regions in HUVEC (Figure 6A-1 
B) as did eNOS (Figure 5C). Interestingly, survivin mRNA expression was reduced when cells 2 
were treated with iCRT5 or FH535, in HUVEC exposed to both UF and DF (Figure 6A and 3 
S4A). Bcl-2 and eNOS expression were also reduced in cells under UF in the presence of 4 
iCRT5. Treatment of HUVEC with ODQ also reduced the expression of eNOS (Figure 6D), 5 
suggesting the presence of a positive feedback mechanism in the eNOS-sGC-β-catenin 6 
pathway. WISP-1 showed very low expression in HUVEC and no differences were found in 7 
expression of XIAP between HUVEC exposed to UF and DF in the presence or absence of 8 
iCRT5 (not shown).  9 
 10 
To identify novel putative genes regulating apoptosis and cell survival in EC exposed to flow, 11 
an apoptosis transcriptome array was performed with HUVEC exposed to UF or DF using an 12 
orbital shaker for 72h (Table S1). We classified the genes up- and downregulated in DF 13 
conditions according to the apoptotic pathways they regulate27 and their function as shown in 14 
Table 1. We observed that the most significant change in EC exposed to DF was the 15 
downregulation of anti-apoptotic genes (Figure 6F and S5). These include members of the 16 
BCL and IAP (inhibitors of apoptosis) families including BIRC5 (survivin), NIAP1, BIRC-2 17 
(cIAP-1), BIRC6, BCL2L2 and MCL-1. Although BIRC3 expression did not change from UF to 18 
DF, it was reduced in EC treated with iCRT5 (Figure S4B) and constitutes a novel target of β-19 
catenin in EC. BIRC2 and BIRC3 are ubiquitin kinases which bind and promote caspase-3 20 
inactivation and degradation28. We validated the expression of cIAP-1 by western blotting in 21 
HUVEC exposed to UF or DF (Figure S4C) and found its expression upregulated in UF-22 
exposed HUVEC as expected, correlating with low levels of caspase-3 in UF-exposed EC. 23 
Treatment of cells with histamine, a pharmacological eNOS activator, that also promotes β-24 
catenin nuclear translocation15, reduced apoptosis in HUVEC exposed to DF (Figure 5E) and 25 
increased the level of survivin (Figure 6E) suggesting a central role for survivin in regulating 26 
cell survival in EC. Together these results support the central role of inhibitors of apoptosis, 27 
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and their positive regulation of expression by β-catenin, in mediating the pro-survival effects 1 
of the eNOS-cGMP pathway in EC exposed to flow.  2 
 3 
Discussion 4 
Phosphorylation of eNOS on Ser1177 is associated with increased eNOS activity and we show 5 
here in static EC that depletion of β-catenin reduced eNOS phosphorylation on Ser1177 in 6 
response to histamine and VEGF stimulation. We also demonstrated increased Ser1177 7 
phosphorylation in EC exposed to UF and found that this was reduced following depletion of 8 
β-catenin. Stabilisation of β-catenin in HUVEC treated with LiCl increased Ser1177 9 
phosphorylation in static and flow exposed EC. We conclude that β-catenin activates eNOS 10 
in human EC.  11 
 12 
We previously reported that eNOS and β-catenin interact in static endothelial cells15. We show 13 
here that eNOS and β-catenin co-localise in regions of UF and DF in the mouse aorta in vivo 14 
with a higher degree of co-localization in the inner aortic arch region, supporting our finding 15 
that eNOS and β-catenin show a higher level of interaction in DF-exposed HUVEC in vitro. 16 
This may reflect higher eNOS activation under UF conditions and subsequent dissociation of 17 
the complex consistent with our finding that acute pharmacological activation of eNOS causes 18 
dissociation from β-catenin15. Since reduced levels of β-catenin associate with reduced eNOS 19 
phosphorylation in HUVEC, it may be that interaction of eNOS and β-catenin facilitates the 20 
access or recruitment of kinases that lead to phosphorylation of eNOS and subsequent 21 
dissociation of β-catenin from the complex. PKA and AKT are kinases that phosphorylate 22 
Ser1177 and activate eNOS in EC in response to different stimuli such as shear stress or 23 
VEGF treatment29. PKA and AKT also phosphorylate and stabilize β-catenin and enhance its 24 
transcriptional activity30. The identification of the putative kinases recruited by β-catenin to 25 
eNOS will be an important area of further study in order to understand the mechanism of action 26 
for the novel β-catenin dependent activation of eNOS described here.   27 
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 1 
We also demonstrate here that β-catenin and sGC signalling are essential mediators of the 2 
pro-survival effects of eNOS in static EC challenged with either TNFa or H2O2 to induce 3 
apoptosis. We previously reported that NO/GMP can stabilise β-catenin leading to 4 
transcriptional changes15. Furthermore, for the first time we present evidence showing that 5 
both NO-cGMP signalling and β-catenin transcriptional activity contribute to maintain cell 6 
survival in ECs under atheroprone flow conditions. HUVEC treated with the sGC inhibitor ODQ 7 
showed an increase in apoptosis in EC exposed to DF that was also observed in both HAEC 8 
and HUVEC treated with iCRT5, a specific inhibitor of β-catenin transcriptional activity. Our 9 
findings are supported by Saran et al.31 who showed that the pro-apoptotic antagonist of Wnt 10 
signalling, sFRP4, causes endothelial dysfunction by suppressing NO-cGMP signalling. 11 
 12 
Wnt/β-catenin promotes cell survival in static EC32, but to our knowledge this is the first study 13 
to show that β-catenin regulates apoptosis in EC exposed to atheroprone disturbed flow. 14 
Several groups have studied the pro-survival and anti-apoptotic effects of undisturbed flow on 15 
EC8,9 and identified GSH and NO as key regulators of cell survival in EC under 16 
atheroprotective flow conditions. Few studies have assessed the differential expression of the 17 
genes and signalling pathways regulating cell survival between disturbed and undisturbed 18 
flow23,24,33. Amini et al. demonstrated that JNK activity/expression was required to drive EC 19 
apoptosis at atheroprone sites in mice. Similarly, PERP, a p53 regulator was found to be 20 
upregulated in atheroprone areas of the porcine aorta, predisposing EC to apoptosis33.  21 
 22 
S-nitrosylation of β-catenin by iNOS can affect junctional permeability34, a characteristic 23 
usually associated with EC exposed to DF. Recent findings suggest that β-catenin S-24 
nitrosylation by eNOS impedes binding to the transcription factor TCF435. This seems to be in 25 
contrast with our and others’ findings suggesting that NO favours β-catenin separation from 26 
VE-cadherin and translocation to the cell nucleus36. In addition to NO, ROS production is 27 
necessary for S-nitrosylation in cells37. ROS increases in EC exposed to DF leading to low NO 28 
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bioavailability due to the reaction of ROS with NO to form peroxynitrite that promotes protein 1 
S-nitrosylation38. S-nitrosylation of β-catenin may explain the fact that we observe reduced 2 
levels of β-catenin dependent gene transcription in DF compared to UF exposed EC. Another 3 
interesting possibility that would need further investigation is that S-nitrosylation may allow β-4 
catenin/TCF to discriminate certain promoters or would allow β-catenin interaction with a 5 
different member of the TCF family to activate cell survival vs proliferation programs (Axin2/ 6 
cyclinD1 vs anti-apoptotic genes).  7 
 8 
β-catenin controls the transcriptional activation of several pro-survival and anti-apoptotic 9 
genes such as WISP-1, Bcl-2 and survivin in static cells39,40. Survivin has previously been 10 
shown to be downregulated in porcine aortic EC exposed to oscillatory flow41 and Bcl-2 has 11 
been reported to be downregulated under low shear stress compared to high shear stress in 12 
HUVEC. Interestingly the expression of Bcl-2 in EC under high shear stress depends on eNOS 13 
activity24. Here we show that in HUVEC, survivin and Bcl-2 are upregulated in EC exposed to 14 
UF compared to DF, confirming the previous findings24,40, and also that their expression is 15 
regulated by β-catenin under flow conditions. In addition, the expression of BIRC3, an inhibitor 16 
of apoptosis family member whose expression is flow independent, was also found to be 17 
positively regulated by β-catenin in HUVEC. Survivin has been identified as a key mediator of 18 
VEGF40 and angiopoietin42,43 induced survival; since both these stimuli activate eNOS activity 19 
their anti-apoptotic actions may be mediated via an NO-driven increase in β-catenin activation 20 
and consequent increase in the transcription of pro-survival/anti-apoptotic genes. We also 21 
observed that survivin expression increased with histamine treatment in HUVEC. The 22 
correlation between survivin expression in EC under flow with NO and β-catenin levels further 23 
supports our finding that β-catenin is a novel mediator of the pro-survival effects of NO, 24 
possibly via regulation of survivin and Bcl-2 expression. Although our experiments have 25 
identified clear changes in survivin and Bcl-2 transcript expression, in future work such 26 
changes in expression will need confirmation also at the protein level. 27 
 28 
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Despite the decreased expression of Bcl-2 and survivin in EC exposed to UF following 1 
inhibition of β-catenin, we saw no accompanying increase in apoptosis. This finding suggested 2 
that other redundant mechanisms exist in cells exposed to UF that protect the cells from pro-3 
apoptotic stimuli resulting in a powerful pro-survival phenotype. Interestingly we found that the 4 
expression of pro-caspase-3 was extremely low in HUVEC exposed to UF when compared to 5 
DF conditions. Since caspase-3 is considered the main executioner caspase in EC, this may 6 
be a parallel regulatory mechanism limiting apoptosis in EC exposed to UF. Caspases are 7 
regulated post-translationally by IAPs (inhibitors of apoptosis), a family of E3 ubiquitin ligases. 8 
In particular caspase-3 activity is regulated by BIRC2 (cIAP1) and BIRC3 (cIAP2), that 9 
ubiquitinate caspases and promote inactivation and/or subsequent degradation by the 10 
proteasome44. In HUVEC, cIAP1 which is upregulated by high shear stress was also shown 11 
to cause a decrease in caspase-3 activity, although caspase expression was not assessed45. 12 
Here we describe for the first time that protein levels of caspase-3 are decreased in EC 13 
exposed to atheroprotective UF.  In our mRNA apoptosis array, BIRC2 (cIAP1) was 14 
upregulated under UF compared to DF and protein expression was confirmed by western 15 
blotting, suggesting that high levels of cIAP1 in EC exposed to UF may contribute to the 16 
degradation and loss of caspase-3 in these cells.  17 
 18 
Our data suggests a bidirectional regulation of the eNOS-β-catenin interaction. Upon eNOS 19 
activation, β-catenin translocates to the nucleus to activate gene transcription but β-catenin 20 
also promotes eNOS activation suggesting that activation of one of the pathways will activate 21 
the other one providing a cross talk between the Wnt/β-catenin and NO. In future work, it 22 
would be instructive to also investigate the role of caspases -8 and -9, which are upstream of 23 
caspase-3, as well as the functional relevance of caspase activation, for example by the use 24 
of pharmacological inhibitors, in the apoptosis pathways investigated here. It will also be 25 
important to dissect in further detail the effects on eNOS phosphorylation observed in our 26 
study, by assaying individual kinases. Nevertheless, our data provide strong evidence of an 27 
21 
 
interaction between two well-established pro-survival pathways and we propose that the 1 
eNOS-cGMP-β-catenin axis is essential to maintain cell survival in EC under disturbed flow.  2 
  3 
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Tables 
 
 
Extrinsic Pathway (Death Receptor) UF DF p-value Fold regulation
Receptors and positive regulators
TNFRSF25 (DR3) 2.0240 0.5587 0.0005 -3.6224
TNFRSF7 (CD27) 0.0702 0.0214 0.0098 -3.2806
TNFRSF6 (FAS) 1.0081 0.4273 0.0001 -2.4041
TNFSF6 (FASLG) 0.0194 0.0095 0.0033 -2.0387
TNFSF5 (CD40LG) 0.0466 0.0237 0.0136 -1.9686
TNFRSF1A (TNFR1) 6.8953 3.7187 0.0265 -1.8542
TNFRSF10B (DR5) 7.3743 4.4220 0.0210 -1.6939
TRAF2 0.6532 0.4123 0.0290 -1.5841
Negative regulators
CFLAR (cFLIP/Casper) 11.0632 5.2331 0.0005 -2.1141
IL10 0.0046 0.0022 0.0449 -2.0572
Intrinsic Pathway (Mitochondrial/DNA Damage) NT UF NT DF p-value Fold regulation
Positive regulators
BCL2L11 0.3164 0.6653 0.0008 2.1026
PYCARD 0.9250 1.9230 0.0067 2.0788
CYCS 0.2805 0.1124 0.0003 -2.4964
APAF1 2.1224 0.9547 0.0032 -2.2230
BIK 0.0158 0.0075 0.0019 -2.1070
TP53BP2 2.2696 1.1816 0.0059 -1.9209
AIFM1 1.2792 0.6753 0.0265 -1.8542
BAK1 0.6385 0.4079 0.0240 -1.5654
Negative regulators
BRAF 0.2838 0.1096 0.0001 -2.5910
BCL2L2 3.6138 1.5032 0.0006 -2.4041
BAG1 0.1032 0.0459 0.0281 -2.2514
MCL1 16.5490 10.5281 0.0263 -1.5719
Executioners NT UF NT DF p-value Fold regulation
NOD1 2.3301 1.0904 0.0001 -2.1370
Caspase 10 2.8597 1.5029 0.0008 -1.9028
Caspase 9 0.9849 0.5731 0.0044 -1.7186
Caspase 8 0.4631 0.2622 0.0067 -1.7663
CIDEB 1.5123 0.8723 0.0228 -1.7336
ABL1 2.3718 1.5154 0.0207 -1.5651
Inhibitors and Negative regulators 
BIRC1 (NAIP) 2.4156 0.6697 0.0015 -3.6072
BIRC6 4.1225 1.5979 0.0001 -2.5799
BIRC2 5.5505 2.7168 0.0007 -2.0430
BIRC5 (Survivin) 0.1991 0.1175 0.0210 -1.6939
NOL3 0.8344 0.5255 0.0061 -1.5877
Table 1: Apoptosis genes regulated by UF and DF in HUVEC 
Gene names are indicated and common synonyms are shown in brackets. UF and DF represent fold change
(2^-DDCt) in mRNA expression compared to the housekeeping gene (HPRT1)in non-treated HUVEC
exposed to UF or DF for 72h, n=3. Fold-regulation is the negative inverse of the fold-change. Fold
regulation values greater than one indicates up-regulation and fold-regulation values less than one
indicate down-regulation. In red are indicated genes that can behave like anti or pro-apoptotic depending
on alternative splicing.
Figure Legends 
Figure 1. β-catenin depletion inhibits agonist induced eNOS phosphorylation in static 
HUVEC. (A-C) HUVEC were transfected with siRNA targeting β-catenin (100 nM) or 
scrambled control siRNA (Scr) and cultured for 72h before treatment for 5 min with vehicle or 
histamine (100 mmol/L). Cell lysates were analysed by western blot using total eNOS, b-
catenin, phospho-Ser1177 (A) or phospho-Ser633 (B) antibodies. (C) cGMP levels were 
quantified by ELISA and results expressed relative to protein content per sample (shown 
relative to scrambled control; n=4). (D-F) HUVEC were cultured for 72h before treatment for 
the indicated times with vehicle or LiCl (20mM). Cell lysates were analysed by western blot 
using total eNOS, phospho-Ser1177 (D) or phospho-Ser633 (E) and b-catenin (F) antibodies. 
(A,B,D,E) Results expressed as the densitometric ratio of phospho-eNOS/GAPDH to total 
eNOS/GAPDH and shown relative to untreated control (n=5); analysis by one-way ANOVA 
with repeated measures, ns: non significant, *p≤0.05, **p≤0.01, ***p≤0.001. 
 
Figure 2. β-catenin mediates the anti-apoptotic effects of NO in static HUVEC. (A) Wild-
type and β-catenin-/- MPECs were treated with SNAP (10 µM) or vehicle. (B) HUVEC were 
transfected with siRNA targeting β-catenin (100 nM)  or scrambled control and cultured for 
72h before treatment with TNFα (10 ng/ml) for 18h in the presence or absence of SNAP (10 
µM).  (A-B) EC were fixed and incubated with anti-cleaved caspase-3 antibody and DAPI. 
Representative images are shown. The percentage of cleaved caspase-3 positive cells was 
calculated in 5 randomly selected fields of view (n=4). (C) HUVEC were transfected with siRNA 
targeting β-catenin (100 nM) or scrambled control and cultured for 72h before treatment with 
H2O2 (200 µM) for 6h in the presence or absence of sildenafil (50 nM; n=4). The bands shown 
by way of example are from the same experiment. (D) HUVEC were treated with H2O2 (200 
µM) for 6h in the presence of SNAP (10 µM), ODQ (10µM) or both in combination (n=3). (C-
D) Cleaved (17kDa and 19kDa) and full length (35kDa) caspase-3 were detected in western 
blots of cell lysates and normalised to β-actin. Densitometry values are shown expressed 
relative to vehicle control. (E) HUVEC were transfected with siRNA targeting β-catenin (100 
nM) or scrambled control and cultured for 72h before treatment with H2O2 (200 µM) for 6h in 
the presence or absence of SNAP (10 µM, following which cells were fixed and DNA 
fragmentation assessed using a Click-IT TUNEL Imaging Kit (n=5), All analyses by one-way 
ANOVA with repeated measures, ns non-significant, *p≤0.05, **p≤0.01, ***p≤0.001. Scale 
bars show 100 mm. 
 
Figure 3: β-catenin interacts with eNOS under flow. (A) HUVEC were exposed to orbital 
flow for 72h, fixed and subject to PLA using antibodies targeting eNOS and b-catenin. In 
control samples PLA was carried out in the absence of b-catenin (I) or eNOS antibody (II). VE-
cadherin and DAPI were used to stain cell junctions and nuclei, respectively. Representative 
images are shown and the average PLA signal quantified in HUVEC under disturbed flow (DF) 
or undisturbed flow (UF; n=4); analysis by paired Student’s t–test, **p≤0.01. (B) EC from 
protected (outer curvature) or atherosusceptible (inner curvature) regions of the mouse aorta 
were stained with eNOS (red) and β-catenin (green) antibodies and imaged en face by 
confocal microscopy. Merged representative images with DAPI (blue) are shown (n=3). Scale 
bars show 50 mm.  
 
Figure 4: β-catenin regulates eNOS under flow. (A) Cell lysates were obtained from 
HUVEC exposed to UF or DF for 72h (n=4). (B) EC transfected with non-targeting scrambled 
or β-catenin targeting siRNA (100 nM) were exposed to orbital flow for 72h (n=5). (C) Cell 
lysates obtained from HUVEC exposed to UF or DF for 72h and treated with vehicle or LiCl 
(20mM) for the last 4h (n=3). (A-C) Cell lysates were analysed by western blot with the 
indicated antibodies. Results are expressed as the densitometric ratio of phospho-
eNOS/eNOS to total eNOS/calnexin and shown relative to levels in UF in vehicle or scr treated 
conditions; analysis by paired Student’s t–test (A) or analysis by one-way ANOVA with 
repeated measures (B-C), *p≤0.05, **p≤0.01, ***p≤0.001.  
 
Figure 5: Inhibition of sGC and β-catenin transcriptional activity increases apoptosis in 
HUVEC exposed to disturbed flow. (A-E) HUVEC were exposed to orbital flow for 72h and 
treated with DMSO, ODQ (10mM) (A), iCRT5 (50 mM) (D) or Histamine (100 mmol/L) (E) for 
the last 24h of flow exposure or transfected with b-catenin or Scr siRNA (100nM) (B). (B) ECs 
were fixed and incubated with a cleaved caspase-3 antibody (green), anti-b-catenin (red) and 
nuclei stained with DAPI. Representative images are shown. (A,B,D,E) The percentage of 
cleaved caspase-3 positive cells was quantified in regions of undisturbed (UF) or disturbed 
flow (DF) (n=3-7). (C) HUVEC were exposed to orbital flow or static conditions for 72h. Full 
length (35 kDa) caspase-3 was detected in western blots of cell lysates. Results are expressed 
as the densitometric ratio of caspase-3 to calnexin. Representative western blots are shown 
(right panel) (n=9); analysis by paired Student’s t–test (C) or analysis by one-way ANOVA with 
repeated measures (A-B,D-E), *p≤0.05, **p≤0.01, ***p≤0.001. Scale bars show 50 mm. 
 
Figure 6. Inhibition of β-catenin downregulates the expression of survivin and Bcl-2 in 
HUVEC exposed to flow. (A-F) HUVEC were exposed to orbital flow for 72h and treated with 
DMSO or iCRT5 (50 µM) (A-C), ODQ (10 mM) (D) or histamine (100 mM) (E) for the last 24h 
of flow or left untreated (F). Transcript levels of survivin (A,E), Bcl-2 (B) and eNOS (C-D) were 
assessed in HUVEC under disturbed flow (DF) or undisturbed flow (UF) by qRT–PCR using 
GAPDH as a housekeeping gene. Values are shown relative to expression in vehicle treated 
HUVEC under UF; analysis by ANOVA with repeated measures (n=3-4); n.s., not significant, 
*p≤0.05, **p≤0.01, ***p≤0.001. (F) mRNA samples from HUVEC exposed to DF or UF were 
analysed using an mRNA expression array targeting 84 apoptotic related genes. HPRT1 was 
used as housekeeping gene (n=3). The Volcano plot shows expression fold change of mean 
across replicates in each condition from DF to UF on x axis (log2) and p-value (-log10) on y 
axis. Significantly differentially expressed genes (p-value < 0.05) are highlighted in red (up-
regulated FC>1.5) or green (down-regulated; FC<-1.5). Relevant genes are indicated.  
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Supplementary Figures and Table 
 
Supplementary Figure S1: β-catenin depletion inhibits agonist induced eNOS 
phosphorylation in static HUVEC. (A-B) HUVEC were transfected with siRNA targeting β-
catenin or scrambled control (Scr) and cultured for 72h before treatment for 5 min with vehicle 
or VEGF (20 nmol/L). Cell lysates were analysed by western blot using anti-β-catenin, total 
eNOS, phospho-Ser1177 (A) or phospho-Ser633 (B) antibodies. Results expressed as the 
densitometric ratio of phospho-eNOS/GAPDH to total eNOS/GAPDH (A-B) and shown relative 
to untreated scrambled control (n=5); analysis by one-way ANOVA with repeated measures, 
n s: non significant, *p≤0.05, **p≤0.01, ***p≤0.001. (C-E) Cell lysates from non treated HUVEC 
transfected with siRNA targeting β-catenin or scrambled control (Scr) were analysed by 
western blot using anti-β-catenin (C,E) total eNOS (D) and GAPDH antibodies and bands 
quantified by densitometry (n=22); analysis by paired student t-test (C-E) or ANOVA with 
repeated measures (A-B); n.s., not significant, *p≤0.05, **p≤0.01, ***p≤0.001. 
 
Supplementary Figure S2: eNOS and β-catenin co-localize in HUVEC. (A) HUVEC were 
exposed to orbital flow for 72h, fixed and stained with eNOS (green), β-catenin (red) and DAPI 
(blue) antibodies. Representative images are shown of HUVEC either in the periphery of the 
well (Undisturbed flow) or in the centre of the well (Disturbed flow). Scale bar represents 50µm. 
(B) HUVEC were exposed to orbital flow for 72h and mRNA samples prepared from EC either 
in the periphery of the well (UF) or in the centre of the well (DF). Transcript levels of KLF2 and 
E-Selectin (ESEL) were assessed by quantitative RT–PCR using GAPDH as a housekeeping 
gene (n=3). (C) Lysates from HUVEC exposed to orbital flow for 72h were obtained and 
separation into a soluble cytoplasm+membrane and nuclear fractions was performed. Lysates 
were analysed by western blotting using β-catenin, lamin B1 and PECAM1 antibodies. 
Densitometry values for the cytoplasmic (β-catenin/PECAM-1) and the nuclear (β-catenin/ 
lamin B1) fractions are shown relative to UF. Representative western blots are shown in right 
panel (n=4). (D) EC transfected with non-targeting scrambled or β-catenin targeting siRNA 
(100 nM) were exposed to orbital flow for 72h. Lysates obtained from UF and DF exposed 
cells were analysed by western blotting, (n=5). Analysis by paired Student’s t–test (B-C) or 
analysis by ANOVA with repeated measures (D), n s: non significant, *p≤0.05, **p≤0.01.  
 
Supplementary Figure S3: β-catenin regulates apoptosis in EC exposed to flow. (A) 
HUVEC were exposed to orbital flow for 72h, fixed and stained with cleaved caspase 3 
(green), active β-catenin (red) and DAPI (blue) antibodies. Representative images are shown 
of HUVEC either in the periphery of the well (UF) or in the centre of the well (DF). Scale bar 
shows 25µm. (B) EC transfected with non-targeting scrambled or β-catenin targeting siRNA 
(100 nM) were exposed to orbital flow and cell lysates analysed by western blot (n=6). (C) 
Lysates from HUVEC exposed to UF or DF for 72h were immunoblotted with caspase 3 and 
calnexin antibodies. Densitometry values are shown relative to UF. Representative western 
blots with calnexin and cleaved caspase 3 (17kDa) are shown in right panel (n=3). (D) HUVEC 
were exposed to orbital flow for 72h and mRNA samples prepared from EC either in the 
periphery of the well (UF) or in the centre of the well (DF). Transcript levels of caspase 3 were 
assessed by quantitative RT–PCR using GAPDH as a housekeeping gene (n=3). (E) HUVEC 
were exposed to orbital flow for 72h and treated with FH535 (50 µM) or DMSO for the last 24h. 
EC were fixed and incubated with an antibody that detects the cleaved form of caspase-3 
(Asp175) and nuclei stained with DAPI. The percentage of cleaved caspase-3 positive cells 
was calculated in the periphery of the well (UF) and in the centre of the cell (DF). Values are 
shown relative to vehicle treated DF (n=3). (F) HAEC were exposed to orbital flow for 72h and 
treated with iCRT5 (50 µM) or DMSO for the last 24h. The relative rate of apoptosis was 
quantified as in D (n=5). (G) HUVEC were exposed to orbital flow for 72h and treated with L-
NAME (100 µM) or left untreated for the last 24h and the relative rate of apoptosis was 
quantified as in D (n=4); analysis by paired Student’s t–test (B-D) or ANOVA with repeated 
measures (E-G); n s: non-significant, *p≤0.05, **p≤0.01, ***p≤0.001. 
 
Supplementary Figure S4: Inhibitors of apoptosis are downregulated in DF exposed 
HUVEC. (A) HUVEC were exposed to orbital flow for 72h and treated with FH535 (25 µM) or 
DMSO for the last 24h. Transcript levels of survivin were assessed by quantitative RT–PCR 
using GAPDH as a housekeeping gene. Values are shown relative to DMSO (n=3). (B) 
HUVEC were exposed to orbital flow for 72h and treated with iCRT5 (50 µM) or DMSO for the 
last 24h. Transcript levels of BIRC3 were assessed as in B (n=3). (C) HUVEC were exposed 
to orbital flow for 72h and protein levels of BIRC2 were assessed in HUVEC under disturbed 
flow (DF) or undisturbed flow (UF) by western blot. Values are shown relative to expression in 
EC under UF. Right panel shows blot representative of n=3; analysis by paired Student’s t–
test (A,C) or one-way ANOVA with repeated measures (B); n s: non significant, *p≤0.05, 
***p≤0.001).  
 
Supplementary Figure S5: Anti-apoptotic genes are down-regulated in EC exposed to 
disturbed flow. HUVEC were exposed to orbital flow for 72h and mRNA samples prepared 
from EC either in the periphery of the well (UF) or in the centre of the well (DF). An mRNA 
expression array targeting 84 apoptotic related genes was performed. HPRT1 was used as 
housekeeping gene (n=3). Significantly differentially expressed genes with a p-value < 0.05 
and with a FC>1.5 or FC<-1.5 were selected as hits. (A) 39% of the genes tested (33 out of 
84) showed at least a 1.5-fold change in expression between DF and UF conditions. Of those, 
31 were genes downregulated in EC exposed to DF compared to UF and only 2 genes were 
found to be upregulated. Of the 84 genes tested, 19 encoded death receptors or ligands, 19 
encoded anti-apoptotic or pro-survival proteins, 27 encoded pro-apoptotic factors, 15 encoded 
effector caspases and other downstream executor proteins [27] and 4 encoded proteins that 
can be pro- or anti-apoptotic (Supplementary Table S1). Both of the genes that were 
upregulated in DF conditions, encoded pro-apoptotic proteins. Of the genes found to be 
downregulated, 35.4% (11 out of 31) encoded anti-apoptotic or pro-survival proteins, 22.5% 
(7 out of 31) pro-apoptotic proteins, 22.5% (7 out of 31) death receptors and 18% (6 out of 31) 
caspases and other executor proteins. The anti-apoptotic genes downregulated in EC 
exposed to DF constitute 57.8% of the anti-apoptotic genes included in the array (11 out of 
19) meanwhile the other genes represented 26.9%, 36.8 % and 33% of the pro-apoptotic, 
receptors and ligands or effector genes tested respectively. (B) Pie chart showing the number 
of hits in each category.  
 
Supplementary Table S1: Summary of apoptosis-related gene expression in HUVEC 
exposed to UF and DF. 
 





 
 
 
 
 
        
Fold 
Regulation p-value  
Position Refseq Symbol Apoptotic pathway/category DF vs UF DF vs UF 
A01 NM_005157 ABL1 Pro-apoptotic -1.5651 0.02068 
A02 NM_004208 AIFM1 Pro-apoptotic -1.8943 0.002535 
A03 NM_005163 AKT1 Anti-apoptotic/pro-survival 1.1985 0.308315 
A04 NM_001160 APAF1 Pro-apoptotic -2.223 0.003211 
A05 NM_004322 BAD Pro-apoptotic 1.3863 0.089515 
A06 NM_004323 BAG1 Anti-apoptotic/pro-survival -2.2514 0.028103 
A07 NM_004281 BAG3 Anti-apoptotic/pro-survival -1.4116 0.007195 
A08 NM_001188 BAK1 Pro-apoptotic -1.5654 0.023977 
A09 NM_004324 BAX Pro-apoptotic -1.0736 0.736664 
A10 NM_003921 BCL10 Pro-apoptotic 1.0144 0.868758 
A11 NM_000633 BCL2 Anti-apoptotic/pro-survival -1.3674 0.086221 
A12 NM_004049 BCL2A1 Anti-apoptotic/pro-survival -2.4236 0.159624 
B01 NM_138578 BCL2L1 Anti-apoptotic/pro-survival 1.001 0.972438 
B02 NM_020396 BCL2L10 Pro-apoptotic -1.1049 0.768924 
B03 NM_006538 BCL2L11 Pro-apoptotic 2.1026 0.000809 
B04 NM_004050 BCL2L2 Anti-apoptotic/pro-survival -2.4041 0.000559 
B05 NM_016561 BFAR Bifunctional (Pro/Anti-apoptotic) -1.2742 0.127776 
B06 NM_001196 BID Pro-apoptotic 1.0543 0.641333 
B07 NM_001197 BIK Pro-apoptotic -2.107 0.001943 
B08 NM_001166 BIRC2 Anti-apoptotic/pro-survival -2.043 0.000747 
B09 NM_001165 BIRC3 Anti-apoptotic/pro-survival -1.0248 0.952439 
B10 NM_001168 BIRC5 Anti-apoptotic/pro-survival -1.6939 0.020966 
B11 NM_016252 BIRC6 Anti-apoptotic/pro-survival -2.5799 0.000076 
 
 
B12 NM_004330 BNIP2 Bifunctional (Pro/Anti-apoptotic) -1.3498 0.173635 
C01 NM_004052 BNIP3 Bifunctional (Pro/Anti-apoptotic) 1.2745 0.027125 
C02 NM_004331 BNIP3L Bifunctional (Pro/Anti-apoptotic) 1.2849 0.153039 
C03 NM_004333 BRAF Pro-apoptotic -2.591 0.000104 
C04 NM_033292 CASP1 Executor and effector proteins -1.226 0.209515 
C05 NM_001230 CASP10 Executor and effector proteins -1.9028 0.000829 
C06 NM_012114 CASP14 Executor and effector proteins -1.5276 0.050478 
C07 NM_032982 CASP2 Executor and effector proteins -1.4381 0.085554 
C08 NM_004346 CASP3 Executor and effector proteins -1.5627 0.053641 
C09 NM_001225 CASP4 Executor and effector proteins -1.0731 0.442365 
C10 NM_004347 CASP5 Executor and effector proteins -1.7717 0.295184 
C11 NM_032992 CASP6 Executor and effector proteins -1.095 0.552437 
C12 NM_001227 CASP7 Executor and effector proteins 1.0731 0.67144 
D01 NM_001228 CASP8 Executor and effector proteins -1.7663 0.006703 
D02 NM_001229 CASP9 Executor and effector proteins -1.7186 0.004419 
        
Fold 
Regulation p-value  
Position Refseq Symbol Apoptotic pathway/category DF vs UF DF vs UF 
D03 NM_001242 CD27 Death receptors and ligands -3.2806 0.009785 
D04 NM_001250 CD40 Death receptors and ligands -1.316 0.325528 
D05 NM_000074 CD40LG Death receptors and ligands -1.9686 0.013581 
D06 NM_001252 CD70 Death receptors and ligands -1.658 0.202356 
D07 NM_003879 CFLAR Anti-apoptotic/pro-survival -2.1141 0.00051 
D08 NM_001279 CIDEA Executor and effector proteins -1.5513 0.228807 
D09 NM_014430 CIDEB Executor and effector proteins -1.7336 0.02284 
D10 NM_003805 CRADD Pro-apoptotic -1.0064 0.972725 
D11 NM_018947 CYCS Pro-apoptotic -2.4964 0.000313 
D12 NM_004938 DAPK1 Pro-apoptotic -1.9165 0.067307 
 
 
E01 NM_004401 DFFA Executor and effector proteins 1.0199 0.811724 
E02 NM_019887 DIABLO Pro-apoptotic -1.3226 0.228869 
E03 NM_003824 FADD Pro-apoptotic 1.0296 0.882835 
E04 NM_000043 FAS Death receptors and ligands -2.3589 0.000088 
E05 NM_000639 FASLG Death receptors and ligands -2.0387 0.003289 
E06 NM_001924 GADD45A Pro-apoptotic 1.1384 0.534175 
E07 NM_003806 HRK Pro-apoptotic -1.4549 0.155279 
E08 NM_000875 IGF1R Anti-apoptotic/pro-survival -1.2957 0.163936 
E09 NM_000572 IL10 Anti-apoptotic/pro-survival -2.0572 0.044915 
E10 NM_000595 LTA Death receptors and ligands -1.0591 0.978922 
E11 NM_002342 LTBR Death receptors and ligands -1.3791 0.057066 
E12 NM_021960 MCL1 Anti-apoptotic/pro-survival -1.5719 0.026338 
F01 NM_004536 NAIP Anti-apoptotic/pro-survival -3.6072 0.00147 
F02 NM_003998 NFKB1 Anti-apoptotic/pro-survival -1.438 0.027655 
F03 NM_006092 NOD1 Executor and effector proteins -2.137 0.000112 
F04 NM_003946 NOL3 Anti-apoptotic/pro-survival -1.5877 0.006106 
F05 NM_013258 PYCARD Pro-apoptotic 2.0788 0.006742 
F06 NM_003821 RIPK2 Pro-apoptotic 1.3458 0.01402 
F07 NM_000594 TNF Death receptors and ligands -1.4549 0.155279 
F08 NM_003844 TNFRSF10A Death receptors and ligands -1.7219 0.099106 
F09 NM_003842 TNFRSF10B Death receptors and ligands -1.6676 0.043374 
F10 NM_002546 TNFRSF11B Death receptors and ligands -1.4796 0.208317 
F11 NM_001065 TNFRSF1A Death receptors and ligands -1.8542 0.02651 
F12 NM_001066 TNFRSF1B Death receptors and ligands -1.1768 0.715645 
G01 NM_014452 TNFRSF21 Death receptors and ligands 1.8737 0.07722 
G02 NM_003790 TNFRSF25 Death receptors and ligands -3.6224 0.000468 
G03 NM_001561 TNFRSF9 Death receptors and ligands -1.2813 0.674319 
G04 NM_003810 TNFSF10 Death receptors and ligands 1.2602 0.171339 
 
 
 
 
 
 
G05 NM_001244 TNFSF8 Death receptors and ligands -1.5442 0.136328 
G06 NM_000546 TP53 Pro-apoptotic 1.3765 0.159191 
G07 NM_005426 TP53BP2 Pro-apoptotic -1.9209 0.005864 
G08 NM_005427 TP73 Pro-apoptotic -1.9914 0.068535 
        
Fold 
Regulation p-value  
Position Refseq Symbol Apoptotic pathway/category DF vs UF DF vs UF 
G09 NM_003789 TRADD Pro-apoptotic -1.4995 0.041893 
G10 NM_021138 TRAF2 Pro-apoptotic -1.5841 0.029047 
G11 NM_003300 TRAF3 Pro-apoptotic -1.0815 0.481774 
G12 NM_001167 XIAP Anti-apoptotic/pro-survival 1.4862 0.744222 
H01 NM_001101 ACTB N/A 1.5942 0.109598 
H02 NM_004048 B2M N/A 1.4349 0.065041 
H03 NM_002046 GAPDH N/A 1.2743 0.3344 
H04 NM_000194 HPRT1 N/A 1 0 
H05 NM_001002 RPLP0 N/A 1.6461 0.013995 
*Bold: Housekeeping gene used for quantification 
  
      
